{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:27:19Z","timestamp":1792722439657,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1053\/beha.2001.0139","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T11:24:48Z","timestamp":1027682688000},"page":"365-379","source":"Crossref","is-referenced-by-count":92,"title":["Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology"],"prefix":"10.1053","volume":"14","author":[{"given":"Jeroen C.J.","family":"Eikenboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/beha.2001.0139_RF1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V70.4.895.895","article-title":"von Willebrand factor and von Willebrand disease","volume":"70","author":"Ruggeri","year":"1987","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1642471","article-title":"A revised classification of von Willebrand disease","volume":"71","author":"Sadler","year":"1994","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF3","first-page":"132","article-title":"Factor VIII-related properties in platelets from patients with von Willebrand's disease","volume":"91","author":"Ruggeri","year":"1978","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"10.1053\/beha.2001.0139_RF4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1172\/JCI108788","article-title":"Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease","volume":"60","author":"Weiss","year":"1977","journal-title":"Journal of Clinical Investigation"},{"key":"10.1053\/beha.2001.0139_RF5","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V87.6.2292.bloodjournal8762292","article-title":"Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C","volume":"87","author":"Koppelman","year":"1996","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2141.1995.tb08921.x","article-title":"Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease","volume":"89","author":"Castaman","year":"1995","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1055\/s-0038-1649813","article-title":"The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey","volume":"74","author":"Foster","year":"1995","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF8","article-title":"Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin","volume":"79","author":"Eikenboom","year":"1998","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF9","first-page":"850","article-title":"Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I","volume":"51","author":"Zhang","year":"1992","journal-title":"American Journal of Human Genetics"},{"key":"10.1053\/beha.2001.0139_RF10","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood.V74.7.2433.2433","article-title":"Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease","volume":"74","author":"Mannucci","year":"1989","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2141.1984.tb02876.x","article-title":"Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel","volume":"57","author":"Mannucci","year":"1984","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0140-6736(93)91070-3","article-title":"Recessive inheritance of von Willebrand's disease type 1","volume":"341","author":"Eikenboom","year":"1993","journal-title":"Lancet"},{"key":"10.1053\/beha.2001.0139_RF13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/BF00191794","article-title":"Effects of the mutant von Willebrand factor gene in von Willebrand disease","volume":"96","author":"Zhang","year":"1995","journal-title":"Human Genetics"},{"key":"10.1053\/beha.2001.0139_RF14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/BF00206958","article-title":"Genetic heterogeneity of severe von Willebrand disease type III in the German population","volume":"94","author":"Schneppenheim","year":"1994","journal-title":"Human Genetics"},{"key":"10.1053\/beha.2001.0139_RF15","doi-asserted-by":"crossref","first-page":"7937","DOI":"10.1073\/pnas.90.17.7937","article-title":"Mutations of von Willebrand factor gene in families with von Willebrand disease in the \u00c5land Islands","volume":"90","author":"Zhang","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1053\/beha.2001.0139_RF16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0038-1650132","article-title":"Recent investigations of the first bleeder family in \u00c5land (Finland) described by von Willebrand","volume":"45","author":"Nyman","year":"1981","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJM198207083070221","article-title":"Incidence of severe von Willebrand's disease","volume":"307","author":"Weiss","year":"1982","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2001.0139_RF18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2141.1986.tb02966.x","article-title":"A relatively high frequency of severe (type III) von Willebrand's disease in Israel","volume":"62","author":"Berliner","year":"1986","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/archinte.1995.00430130095010","article-title":"Usefulness of patient interview in bleeding disorders","volume":"155","author":"Sr\u00e1mek","year":"1995","journal-title":"Archives of Internal Medicine"},{"key":"10.1053\/beha.2001.0139_RF20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/262141a0","article-title":"Precipitating antibodies in von Willebrand's disease","volume":"262","author":"Mannucci","year":"1976","journal-title":"Nature"},{"key":"10.1053\/beha.2001.0139_RF21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02919121","article-title":"Alloantibodies in congenital von Willebrand's disease","volume":"21","author":"Mannucci","year":"1991","journal-title":"Research in Clinic and Laboratory"},{"key":"10.1053\/beha.2001.0139_RF22","series-title":"Hemophilia and von Willebrand's disease in the 1990s","first-page":"481","article-title":"Alloantibodies in congenital von Willebrand's disease","author":"Mannucci","year":"1991"},{"key":"10.1053\/beha.2001.0139_RF23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s002770050323","article-title":"Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor\u2013FVIII interaction","volume":"75","author":"Batlle","year":"1997","journal-title":"Annals of Hematology"},{"key":"10.1053\/beha.2001.0139_RF24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0037-1613799","article-title":"Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease","volume":"83","author":"Tout","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood.V72.1.116.bloodjournal721116","article-title":"Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease","volume":"72","author":"Lopez-Fernandez","year":"1988","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V57.1.25.25","article-title":"Precipitating antibodies to factor VIII\/von Willebrand factor in von Willebrand's disease: effects on replacement therapy","volume":"57","author":"Mannucci","year":"1981","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0609.1987.tb01458.x","article-title":"Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor","volume":"39","author":"Mannucci","year":"1987","journal-title":"European Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF28","first-page":"348","article-title":"Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor","volume":"125","author":"Bergamaschini","year":"1995","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"10.1053\/beha.2001.0139_RF29","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1073\/pnas.85.8.2753","article-title":"Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease","volume":"85","author":"Ngo","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1053\/beha.2001.0139_RF30","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI112974","article-title":"Gene deletions correlate with the development of alloantibodies in von Willebrand disease","volume":"79","author":"Shelton-Inloes","year":"1987","journal-title":"Journal of Clinical Investigation"},{"key":"10.1053\/beha.2001.0139_RF31","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V75.3.654.654","article-title":"Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual","volume":"75","author":"Peake","year":"1990","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0038-1648835","article-title":"Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors","volume":"72","author":"Mancuso","year":"1994","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF33","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1055\/s-0037-1614063","article-title":"Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease","volume":"84","author":"Baronciani","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF34","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease","volume":"1","author":"Mannucci","year":"1977","journal-title":"Lancet"},{"key":"10.1053\/beha.2001.0139_RF35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.1981.tb02789.x","article-title":"Response of factor VIII\/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease","volume":"47","author":"Mannucci","year":"1981","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF36","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2141.1994.tb04735.x","article-title":"Patients with severe von Willebrand disease are insensitive to the releasing effect on DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor","volume":"86","author":"Cattaneo","year":"1994","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/joim.1997.242.s740.129","article-title":"Treatment of von Willebrand's disease","volume":"242","author":"Mannucci","year":"1997","journal-title":"Journal of Internal Medicine"},{"key":"10.1053\/beha.2001.0139_RF39","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1182\/blood.V74.6.1972.1972","article-title":"DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor","volume":"74","author":"Cattaneo","year":"1989","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1423-0410.1992.tb01198.x","article-title":"Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease","volume":"62","author":"Rodeghiero","year":"1992","journal-title":"Vox Sanguinis"},{"key":"10.1053\/beha.2001.0139_RF41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2141.1992.tb08903.x","article-title":"Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity","volume":"80","author":"Goudemand","year":"1992","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1055\/s-0038-1657591","article-title":"Recombinant von Willebrand factor","volume":"78","author":"Schwarz","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF43","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","article-title":"Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial","volume":"79","author":"Mannucci","year":"1992","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-0609.1988.tb00825.x","article-title":"Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates","volume":"40","author":"Berntorp","year":"1988","journal-title":"European Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1365-2516.1998.0040s3040.x","article-title":"In vitro evaluation of the haemostatic value of the LFB-von Willebrand factor concentrate","volume":"4","author":"Mazurier","year":"1998","journal-title":"Haemophilia"},{"key":"10.1053\/beha.2001.0139_RF46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00001721-199304060-00018","article-title":"Biological effects of S\/D-treated very high purity von Willebrand factor concentrate in five patients with severe von Willebrand disease","volume":"4","author":"Meriane","year":"1993","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1053\/beha.2001.0139_RF47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x","article-title":"Clinical management of patients with von Willebrand's disease with VHP vWF concentrate: the French experience","volume":"4","author":"Goudemand","year":"1998","journal-title":"Haemophilia"},{"key":"10.1053\/beha.2001.0139_RF48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2516.1998.0040s3011.x","article-title":"Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP\u2013a survey of European physicians","volume":"4","author":"Lusher","year":"1998","journal-title":"Haemophilia"},{"key":"10.1053\/beha.2001.0139_RF49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2516.1998.0040s3007.x","article-title":"Optimizing therapy with factor VIII\/von Willebrand factor concentrates in von Willebrand disease","volume":"4","author":"Federici","year":"1998","journal-title":"Haemophilia"},{"key":"10.1053\/beha.2001.0139_RF50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002770050542","article-title":"The platelet function analyzer (PFA-100) may not be suitable for monitoring the therapeutic efficiency of von Willebrand concentrate in type III von Willebrand disease","volume":"78","author":"Meskal","year":"1999","journal-title":"Annals of Hematology"},{"key":"10.1053\/beha.2001.0139_RF51","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1365-2141.1999.01604.x","article-title":"Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates","volume":"106","author":"Fressinaud","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0037-1614626","article-title":"Evaluation of the PFA-100(R) system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease","volume":"82","author":"Cattaneo","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF53","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.V77.9.1901.1901","article-title":"Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients","volume":"77","author":"Castillo","year":"1991","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF54","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00001721-199112000-00013","article-title":"Treatment of the severe bleeding episode in type III von Willebrand's disease by simultaneous administration of cryoprecipitate and platelet concentrate","volume":"2","author":"Boda","year":"1991","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1053\/beha.2001.0139_RF55","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1046\/j.1537-2995.1997.37897424399.x","article-title":"Hemostatis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect","volume":"37","author":"Castillo","year":"1997","journal-title":"Transfusion"},{"key":"10.1053\/beha.2001.0139_RF56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1055\/s-0037-1613882","article-title":"Recombinant factor VIIa is a pan-hemostatic agent","volume":"83","author":"Aledort","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF57","first-page":"150","article-title":"Use of recombinant factor VIIa (NovoSeven(R)) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor","volume":"26","author":"Ciavarella","year":"1996","journal-title":"Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0037-1613878","article-title":"Continuous infusion of recombinant factor VIIa (NovoSeven(R)) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor","volume":"83","author":"Grossmann","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0049-3848(79)90156-7","article-title":"Apparent \u2018dominant\u2019 and \u2018recessive\u2019 inheritance of von Willebrand's disease within the same kindreds. Possible biochemical mechanisms","volume":"15","author":"Bloom","year":"1979","journal-title":"Thrombosis Research"},{"key":"10.1053\/beha.2001.0139_RF60","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1056\/NEJM197310252891703","article-title":"Detection of heterozygotes for recessive von Willebrand's disease by the assay of antihemophilic-factor-like antigen","volume":"289","author":"Veltkamp","year":"1973","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2001.0139_RF61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0038-1651577","article-title":"A database of polymorphisms in the von Willebrand factor gene and pseudogene","volume":"69","author":"Sadler","year":"1993","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF62","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V76.3.555.555","article-title":"Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene","volume":"76","author":"Peake","year":"1990","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF63","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2141.1990.tb07879.x","article-title":"Family studies in von Willebrand's disease by analysis of restriction fragment length polymorphisms and an intragenic variable number tandem repeat (VNTR) sequence","volume":"76","author":"Standen","year":"1990","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2141.1988.tb06196.x","article-title":"von Willebrand disease investigated by two novel RFLPs","volume":"68","author":"Bernardi","year":"1988","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/s-0038-1647025","article-title":"Carrier detection in severe (type III) von Willebrand disease using two intragenic restriction fragment length polymorphisms","volume":"60","author":"Bahnak","year":"1988","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2141.1990.tb02619.x","article-title":"An infrequent DNA polymorphism associated with severe von Willebrand's disease","volume":"75","author":"Caekebeke-Peerlinck","year":"1990","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF67","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.1990.tb02584.x","article-title":"Characterization of polymorphic markers in the von Willebrand factor gene and pseudogene","volume":"74","author":"Bernardi","year":"1990","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001721-199204000-00005","article-title":"The inheritance of type I and type III von Willebrand's disease in Israel: linkage analysis, carrier detection and prenatal diagnosis using three intragenic restriction fragment length polymorphisms","volume":"3","author":"Inbal","year":"1992","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1053\/beha.2001.0139_RF69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-0038-1651576","article-title":"von Willebrand disease: a database of point mutations, insertions, and deletions","volume":"69","author":"Ginsburg","year":"1993","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF70","first-page":"283","article-title":"Mutational analysis of the von Willebrand factor gene in 27 families from Turkey with von Willebrand disease","volume":"82","author":"Abuzenadah","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF71","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1073\/pnas.88.9.3857","article-title":"Severe von Willebrand disease due to a defect at the level of von Willebrand factor mRNA expression: detection by exonic PCR-restriction fragment length polymorphism analysis","volume":"88","author":"Nichols","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1053\/beha.2001.0139_RF72","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/s-0038-1646295","article-title":"Mutations in severe, type III von Willebrand's disease in the Dutch population: candidate missense and nonsense mutations associated with reduced levels of von Willebrand factor messenger RNA","volume":"68","author":"Eikenboom","year":"1992","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF73","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V78.4.1148.1148","article-title":"A stop codon in a patient with severe type III von Willebrand disease","volume":"78","author":"Bahnak","year":"1991","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/hmg\/1.1.61","article-title":"Identification of a new nonsense mutation in the von Willebrand factor gene in patients with von Willebrand disease type III","volume":"1","author":"Zhang","year":"1992","journal-title":"Human Molecular Genetics"},{"key":"10.1053\/beha.2001.0139_RF75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/geno.1994.1241","article-title":"Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin","volume":"21","author":"Zhang","year":"1994","journal-title":"Genomics"},{"key":"10.1053\/beha.2001.0139_RF76","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-0038-1650564","article-title":"A novel mutation Gly1672\u2192Arg in type 2A and a homozygous mutation in type 2B von Willebrand disease","volume":"76","author":"Hagiwara","year":"1996","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF77","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/hmg\/1.9.767","article-title":"A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients","volume":"1","author":"Zhang","year":"1992","journal-title":"Human Molecular Genetics"},{"key":"10.1053\/beha.2001.0139_RF78","first-page":"94b","article-title":"Delta C in exon 18 of the von Willebrand factor gene is the most common mutation in patients with severe von Willebrand disease type 3 in Poland","volume":"90","author":"Gazda","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF79","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1046\/j.1365-2141.1996.7572377.x","article-title":"A common frameshift mutation in von Willebrand factor does not alter mRNA stability but inferferes with normal propeptide processing","volume":"95","author":"Mohlke","year":"1996","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF80","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2141.1993.tb03114.x","article-title":"Instability of repeats of the von Willebrand factor gene variable number tandem repeat sequence in intron 40","volume":"84","author":"Eikenboom","year":"1993","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/geno.1994.1602","article-title":"A G+3-to-T donor splice site mutation leads to skipping of exon 50 in von Willebrand factor mRNA","volume":"24","author":"Mertes","year":"1994","journal-title":"Genomics"},{"key":"10.1053\/beha.2001.0139_RF82","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2141.2000.01807.x","article-title":"Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation","volume":"108","author":"Castaman","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2001.0139_RF83","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood.V96.2.560","article-title":"A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion","volume":"96","author":"Allen","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2001.0139_RF84","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1083\/jcb.113.1.195","article-title":"Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids","volume":"113","author":"Voorberg","year":"1991","journal-title":"Journal of Cellular Biology"},{"key":"10.1053\/beha.2001.0139_RF85","first-page":"283","article-title":"Cysteine mutations of von Willebrand factor correlate with different types of von Willebrand disease","volume":"82","author":"Schneppenheim","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1053\/beha.2001.0139_RF86","first-page":"443a","article-title":"A homozygous variant of von Willebrand factor (VWF) that fails to C terminal dimerize resulting in loss of VWF multimers larger than dimer","volume":"94","author":"Montgomery","year":"1999","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692601901392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692601901392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T21:29:27Z","timestamp":1581024567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692601901392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["S1521692601901392"],"URL":"https:\/\/doi.org\/10.1053\/beha.2001.0139","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}